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Abstract
Background: We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure
interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Methods: We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, Chemotherapy, and
Stem Cell Transplantation (SCT), each compared to ART. Efficacy and cost parameters were varied widely in sensitivity
analysis. Outcomes included quality-adjusted life expectancy, lifetime cost, and cost-effectiveness in dollars/quality-adjusted
life year ($/QALY) gained. Strategies were deemed cost-effective with incremental cost-effectiveness ratios ,$100,000/
QALY.
Results: For patients on ART, discounted quality-adjusted life expectancy was 16.4 years and lifetime costs were $591,400.
Gene Therapy was cost-effective with efficacy of 10%, relapse rate 0.5%/month, and cost $54,000. Chemotherapy was cost-
effective with efficacy of 88%, relapse rate 0.5%/month, and cost $12,400/month for 24 months. At $150,000/procedure, SCT
was cost-effective with efficacy of 79% and relapse rate 0.5%/month. Moderate efficacy increases and cost reductions made
Gene Therapy cost-saving, but substantial efficacy/cost changes were needed to make Chemotherapy or SCT cost-saving.
Conclusions: Depending on efficacy, relapse rate, and cost, cure strategies could be cost-effective compared to current ART
and potentially cost-saving. These results may help provide performance targets for developing cure strategies for HIV.
Citation: Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, et al. (2014) HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral
Therapy? PLoS ONE 9(11): e113031. doi:10.1371/journal.pone.0113031
Editor: Nicolas Sluis-Cremer, University of Pittsburgh, United States of America
Received September 5, 2014; Accepted October 17, 2014; Published November 14, 2014
Copyright:  2014 Sax et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files. Additional information about model structure, inputs, and results are available at the CEPAC website (http://web2.research.partners.
org/cepac/model.html). De-identified patient data that serve as model inputs have been published and are available through the references cited in the
manuscript.
Funding: This research was funded by the National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/Pages/default.aspx): R37 AI042006 (PS,
AS, BB, BM, EL, ADP, KK, RW, MW, KF), AI051966 (GS), R01 AI093269 (RW, KF, ADP, MW), U01 AI 069472 (PS, EL, KF, RQ, ADP, AS, BB, BM, KK) (Partners/Harvard AIDS
Clinical Trials Unit), U01 AI068636 (PS, EL, KF, RQ, ADP, AS, BB, BM, KK) (Central AIDS Clinical Trials Group), and UM1 AI 069423 (JE) (UNC Global Clinical Trials Unit).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Sax has served as a consultant to AbbVie, BMS, Gilead, GSK, Merck and Janssen, and has received grant support from BMS, Gilead, and
GSK. Dr. Weinstein serves as a consultant to OptumInsight for work unrelated to the submitted research. Dr. Eron has served as a consultant to Abbvie, BMS,
Gilead, GSK, Merck, Janssen and ViiV, and has received grant support from BMS, ViiV and Merck. All other authors report no conflicts of interest. This does not alter
the authors’ adherence to PLOS ONE policies on sharing data and materials.
* Email: psax@partners.org
Introduction
Combination antiretroviral therapy (ART) durably controls
HIV replication and halts progression of clinical HIV disease in
the vast majority of patients who receive and continue treatment
[1]. Projected survival for people with HIV is now estimated to be
several decades. Some reports suggest that survival for people with
HIV on successful therapy approaches that of those without
infection if therapy is initiated early and HIV suppression is
sustained [2].
Despite the remarkable success of treatment, ART nonetheless
has many limitations. Although much less toxic than earlier
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113031regimens, current treatment still may be associated with cardio-
vascular, renal, bone, and other complications [3,4]. The
inflammation and immune activation that persist in many patients
on suppressive ART may have long-term negative consequences
[5]. Therapy in the US and Europe remains costly, and, because
not curative, it must be continued indefinitely [6,7]. Successful
ART also does not eliminate the stigma associated with HIV
infection [8].
The first report of successful HIV cure after allogeneic stem cell
transplant for acute leukemia demonstrated that eradicating HIV
from an individual is viable [9]. While allogeneic transplant in the
absence of usual indications carries substantial risk, cost, and post-
transplant consequences of chronic immunosuppression, other
strategies are being studied that could potentially cure HIV and be
practically deployed [10–12]. In this analysis we aim to establish
thresholds of efficacy, toxicity, durability, cost, and quality of life
necessary for a cure strategy to compare favorably with current
antiretroviral therapy in the United States.
Methods
Analytic Overview
To analyze the potential life expectancy and cost-effectiveness of
HIV cure strategies under study, we utilized the Cost-Effectiveness
of Preventing AIDS Complications (CEPAC) model, a Monte-
Carlo microsimulation of HIV disease and treatment [13]. We
completed a ‘what if’ analysis, in order to understand the possible
role of HIV cure strategies as they are developed. Model outputs
included life expectancy, quality-adjusted life expectancy, and
lifetime costs (2012 USD), all discounted to present value at 3%
annually [14]. Incremental cost-effectiveness ratios (ICERs) were
calculated by comparing each hypothetical cure strategy to the
standard of care, lifelong ART. We determined parameter
thresholds at which potential cure strategies were either cost-
effective, defined as ICERs ,$100,000/quality-adjusted life year
(QALY), or cost-saving compared to current ART [15].
Strategies Evaluated
We evaluated three hypothetical HIV cure strategies: a ‘‘low
efficacy,’’ ‘‘low risk’’ gene therapy approach (Gene Therapy); a
‘‘moderate efficacy,’’ ‘‘moderate risk’’ chemotherapy approach
(Chemotherapy); and a ‘‘high efficacy,’’ ‘‘high risk’’ allogeneic
stem cell transplant (SCT). Costs of these strategies would likely
vary widely and are currently uncertain.
The Gene Therapy strategy was modeled after the use of zinc
finger nucleases to modify the CCR5 receptor on the surface of
CD4 cells [12]. Patients undergo pheresis, their cells are modified
using zinc finger nucleases, and re-infused with the goal of
establishing a CCR5-negative cell population that is resistant to
HIV infection. Based on preliminary reports, this type of
procedure would have lower risk and toxicity than Chemotherapy
and SCT and, we assumed, lower likelihood of achieving cure
[16–19]. Simulated patients were modeled to receive the benefit of
cure one month after Gene Therapy, if effective. Input parameters
for all strategies were varied widely in sensitivity analysis, as
described below.
The Chemotherapy intervention was derived from both in vitro
and in vivo experiments using histone deacetylase inhibitors (such
as vorinostat) to stimulate and eliminate the HIV viral reservoir
[10]. Simulated patients received ART combined with Chemo-
therapy for 96 weeks, after which, if effective, they had the benefit
of cure. There was increased cost and toxicity for the chemother-
apy-based administration of vorinostat [17,20].
SCT had the highest assumed risk of mortality and toxicity, but
was assumed the most effective. Simulated SCT patients received
the benefit of cure in the first month after successful transplant.
The Cost-Effectiveness of Preventing AIDS Complications
(CEPAC) Model
Simulations were performed using the CEPAC model, a widely-
published, validated state-transition microsimulation of HIV
disease [13]. HIV natural history is modeled as a series of
monthly transitions between health states characterized by CD4
count and HIV RNA. Without treatment, patients’ CD4 counts
decline according to a viral load-dependent trajectory [21].
Patients are also subject to age- and sex-specific non-HIV-related
mortality [22].
Once patients initiate ART, the probability of virologic
suppression and subsequent CD4 count increases, with the
greatest CD4 gain occurring in the first two months [23]. CD4
count gains are associated with reduced risk of developing
opportunistic infections and HIV-related death. Patients’ HIV
RNA and CD4 counts are routinely monitored to detect treatment
failure. Upon virologic rebound, patients switch to the next
available ART regimen. Costs of HIV treatment and care are
from the health system perspective and derived from HIV
Research Network data and the Medicare fee schedule [24–27].
Cure Simulation
This analysis focused on patients who had received fully
suppressive first-line ART for one year and were thereby eligible
for a cure strategy, as is the case in planned or ongoing cure trials
[28]. We maintained the CD4 benefit associated with virologic
suppression for each cure strategy. With each cure regimen,
patients faced strategy-specific probabilities of achieving cure as
well as toxicity, quality of life (QOL) decrements and increases
(associated with both toxicity and the regimen itself), and monthly
probabilities of relapse. Additionally, patients accrued strategy-
specific intervention costs. Cured patients were no longer subject
to monthly probabilities of opportunistic infections and AIDS-
related death, but were subject to monthly probabilities of relapse
and subsequent return to ART. After cure, patients faced monthly
probabilities of non-AIDS mortality and accrued monthly costs for
routine care and continued HIV RNA monitoring for relapse.
Patients who failed cure, or later relapsed after cure, resumed first-
line ART, followed by additional ART regimens if virologic failure
occurred later.
Model Inputs and Analysis
We used the CEPAC model itself to determine the distribution
of CD4 counts in the eligible population by simulating a cohort of
patients entering the model with the age, sex, and CD4 count
distribution of HIV-infected patients in North America at care
presentation. Patients were given a first-line ART regimen of
efavirenz, tenofovir, and emtricitabine for one year [29]. Per
current guidelines, all patients received ART, regardless of CD4
count [30]. Following one year on suppressive ART, patients
became eligible for a cure intervention, beginning these cure
strategies with mean CD4 count of 564/ml (SD 250/ml), based on
this initialization.
Patients assigned to a cure intervention were subject to a
strategy-specific probability of being cured (Table 1). All efficacies
were hypothetical, since cure interventions do not currently exist.
Cured patients had undetectable viremia for the duration of their
lifetimes, unless they relapsed. We assumed relapse rates were
highest during the first five years after a cure intervention (0.5%/
HIV Cure Strategies Compared to ART
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(0.25%/month). Relapse was detected through routine virologic
monitoring. Both acute and chronic non-fatal toxicities resulted in
a QOL decrement of 0.04, which lasted one month for acute non-
fatal toxicities and until the patient failed the cure strategy for
chronic toxicities [31]. Because the cohort was comprised only of
patients virologically suppressed on first-line ART for one year, we
assumed high rates of virologic re-suppression after a failed cure
intervention. Those patients were also at risk for later virologic
failure, at a rate of 0.13%/month [32]. Costs associated with each
of the interventions and their associated toxicities were based on
reported costs for similar procedures for other conditions
(Table 1). In the base case, we assumed no additional QOL
benefit related to achieving HIV cure compared to being on
effective ART. In sensitivity analyses, we considered scenarios in
which cured patients had an increase in their QOL from the base
case. Any QOL benefit was suspended if the patient relapsed and
re-initiated ART.
Gene Therapy was assumed to have an efficacy of 10.0% with
no risk of fatal toxicity [16]. Patients incurred a 25.0% risk of
acute, non-fatal toxicity (e.g., headache or oropharyngeal pain)
lasting for one month [16]. While receiving Gene Therapy,
patients incurred an immediate cost of $100,000, based on current
estimates for gene therapies, plus $2,000 for continued ART (from
weighted average of current drug prices) during the month they
received Gene Therapy [20,33,34]. This intervention cost was
based on ivacaftor, an oral cystic fibrosis medication that acts on
the genetic mutation causing the disease [20].
Chemotherapy was assumed to have an efficacy of 20.0%, and
1.2% probability of fatal toxicity [17]. Patients incurred a 6.0%
risk of acute non-fatal toxicity and 5.8% risk of chronic non-fatal
toxicity [17,18]. Chemotherapy was modeled as a 96-week course
(24 months) with monthly costs of $12,400; $2,000/month was
included for maintenance ART [17]. At any point in the 96-weeks
patients could fail ART and experience HIV virologic rebound.
Patients who had not experienced ART failure during the 96
weeks could be cured at the end of that period (assumed efficacy
20.0%).
SCT was assumed to have an efficacy of 70.0%, with 5.0%
mortality from the procedure [35]. Patients had a 47.3%
probability of acute graft-versus-host disease and 37.2% probabil-
ity of chronic graft-versus-host-disease [19]. The initial cost of the
transplant was assumed to be $150,000 with monthly costs of
$1,000 for six months for immunosuppressive medications [36,37].
Sensitivity Analysis
Because the focus of this analysis was on strategies under
research and development, we conducted extensive sensitivity
analysis on all cure parameters to identify those most important in
changing the main conclusions. For each cure strategy and
parameter, we determined thresholds at which the strategy would
become cost-effective at a threshold of $100,000/QALY, as well as
become cost-saving compared to ART. For sensitivity analyses
involving relapse rates, early (#5 years) and late (.5 years) relapse
rates were varied together. Recognizing the impact a cure might
have on patients’ well-being (physical, emotional, and social), we
Table 1. Parameter inputs for a model-based analysis of potential HIV cure strategies.
Variable: Base Case
(Range)
Gene
Therapy Chemotherapy
Stem Cell
Transplant References
Cohort Characteristics
CD4 count, mean cells/ml (SD) 564 (250) 564 (250) 564 (250) See Methods
a
Age, mean years (SD) 44 (12) 44 (12) 44 (12) [29]
Percent male 84 84 84 [29]
Cure Characteristics
Efficacy (%) 10.0
(10.0–90.0)
20.0
(10.0–90.0)
70.0
(10.0–90.0)
Assumptions
Monthly relapse rate (%),
early/late
0.50/0.25
(0.0–2.0)
0.50/0.25
(0.0–2.0)
0.50/0.25
(0.0–2.0)
Assumptions
Initial cost ($) 100,000
(50,000–200,000)
12,400/month
b
(6,200–24,800)
150,000
(75,000–300,000)
Assumptions based on
[20,33,34,36]/[20]/[36]
Additional cost ($, while on cure
regimen only)
2,000/month
c 2,000/month
c 1,000/month
d
(for 6 months)
[20,34]/[20,34]/[37]
Fatal Toxicity
Probability (%) 0.0 1.2 5.0 Assumption based on [16]/[17]/[35]
Cost ($) – 63,110 63,110 Derived from [24,25,27,46]
Acute Non-fatal Toxicity
Probability (%) 25.0 6.0 47.3 Assumption based on Ivacaftor package
insert [16]/[18]/[19]
Cost ($) 50 3,100 18,700 [25]/[47]/Derived from [48]
Chronic Non-fatal Toxicity
Probability (%) 0.0 5.8 37.2 Assumption based on [16]/[18]}/[19]
Cost ($) – 1,040 1,900 [49]/Derived from [50]
SD: standard deviation; QOL: quality-of-life.
aDetermined through initialization run of simulated cohort;
bFor 24 months based on vorinostat;
cFor monthly antiretroviral therapy, derived from weighted averages of
current therapies until gene- or chemo-therapy is complete;
dFor immunosuppressive agents, including methotrexate with tacrolimus.
doi:10.1371/journal.pone.0113031.t001
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prior to and following HIV cure. Due to the major toxicity,
including fatal toxicity, involved in SCT, we focused the QOL
sensitivity analysis on the Gene Therapy and Chemotherapy
strategies.
Ethics Statement
This study was reviewed and approved by the Partners Heath
Care Human Research Committee (Protocol 2000P001927),
Boston, Massachusetts, USA, as it was determined to meet the
criteria for exemption from human studies. A waiver for written
informed consent from participants was not necessary because
only secondary data were used in this study and no human subjects
were involved. Secondary patient data that serve as our model
inputs were anonymized and de-identified prior to analysis.
Results
Base Case Scenarios
The standard of care (lifelong ART) had a discounted projected
life expectancy of 19.0 years (16.4 QALYs) and discounted lifetime
cost of $591,400. Undiscounted life expectancy with standard of
care was 32.3 years, compared to 32.8, 32.3, and 32.6 years, for
Gene Therapy, Chemotherapy, and SCT under the base case set
of assumptions. Gene Therapy (10% efficacy) resulted in a
discounted life expectancy of 19.3 years (16.6 QALYs) and
increased discounted lifetime costs to $658,700, for an ICER of
$330,600/QALY gained compared to continued ART. Chemo-
therapy (20% efficacy) led to a discounted life expectancy of 19.0
years (16.4 QALYs) and discounted lifetime cost of $807,300, and
was more expensive and less effective than ART. SCT resulted in
a discounted life expectancy of 19.0 years (16.3 QALYs) and
increased costs to $607,400; it was also more expensive and less
effective than ART (Table 2).
One-way Sensitivity Analyses
With efficacy increased to 22% and other inputs remaining the
same, Gene Therapy had an ICER ,$100,000/QALY, and at an
efficacy of 34% became cost-saving, relative to ART (Table 3).
With a reduced cost of $54,000, Gene Therapy achieved an
ICER,$100,000/QALY gained even at 10% efficacy; it was cost-
saving at $34,000. Chemotherapy was not cost-effective unless
efficacy increased to 88% and was not cost-saving at any efficacy.
Varying any other single parameter within reasonable limits did
not result in Chemotherapy reaching thresholds for cost-effective-
ness or cost savings (Table 3). The efficacy threshold for SCT was
79% to achieve cost-effectiveness and 80% to achieve cost savings.
Reducing fatal toxicity to 3.0% from 5.0% also led to SCT
becoming cost-effective (Table 3).
Multiway Sensitivity Analyses
With no relapse risk, Gene Therapy was cost-saving with
efficacy of at least 30%. With increasing relapse rates, higher
efficacy was required to achieve cost savings. At a decreased cost of
$50,000, Gene Therapy became cost-effective at the base case
values for relapse and efficacy and cost-saving with lower relapse
rates or higher efficacies (Figure 1). At increased cost of $200,000,
the intervention was not cost-effective compared to standard of
care ART for almost all combinations of input parameters
(Figure 1).
For Chemotherapy, at the base case cost and relapse rate of
greater than 0.5%/month, the intervention was never cost-
effective (Figure 2). With no relapse risk, the intervention was
not cost-effective at efficacies of 20–50% but was cost-saving at
efficacies above 60%. If the cost was halved ($6,200/month),
Chemotherapy was cost-saving at substantially lower efficacies and
higher relapse rates than in the base case. For example, at this
decreased cost, Chemotherapy was cost-saving with relapse rate of
0.5%/month with efficacy 60%. If the cost of Chemotherapy was
doubled to $24,800/month, it was not cost-effective with any
combination of efficacy (20–90%) and relapse rate (0.0–2.0%).
The window for cost-effectiveness was narrow; with most
parameter combinations, Chemotherapy was either cost-saving
or not cost-effective.
In most sensitivity analyses, SCT was not cost-effective. In
selected cases where the cost was extremely low or efficacy very
high, SCT became cost-saving (Figure 3). For one parameter
combination, SCT was less effective and less expensive than ART,
but it was not cost-effective because the ICER of ART was ,
$100,000/QALY compared to SCT. If the cost of SCT was
halved ($75,000), the combinations where the intervention was
cost-saving remained roughly the same, but several scenarios that
were not cost-effective in the base case became less expensive and
less effective than ART.
With an efficacy of 10% for Gene Therapy, improving QOL to
a utility of 1.00 (i.e., the equivalent of perfect health) after
successful cure would be insufficient to achieve an ICER ,
$100,000/QALY gained. With efficacy of 20%, however, an
ICER ,$100,000/QALY gained could be achieved if patient
utility following cure increased from 0.85 to 0.88, or the equivalent
of facing a 3% decreased risk of death every year. For efficacies of
30% or more, the Gene Therapy strategy would always be cost-
effective, regardless of whether the cure had any impact on QOL.
At the base-case QOL utility of 0.85, Chemotherapy was not cost-
effective at any efficacy below 60%, even with the maximum QOL
improvement. At an efficacy of 60% for Chemotherapy, cost-
effectiveness could be achieved if patient utility following cure
increased from 0.85 to 0.97. If the baseline QOL utility while
living with HIV were 0.50, Chemotherapy would not reach the
Table 2. Base case results of an analysis of hypothetical HIV cure strategies*.
Strategy
Discounted Life
Years
(Undiscounted)
Discounted
QALYs Cost ($)
Incremental Cost-effectiveness compared
to standard of care ($/QALY)
Standard of care ART 19.0 (32.3) 16.4 591,400 –
Gene Therapy 19.3 (32.8) 16.6 658,700 330,600
Chemotherapy 19.0 (32.3) 16.4 807,300 Dominated
Stem Cell Transplant 19.0 (32.6) 16.3 607,400 Dominated
*Based on assumptions for efficacy, durability, toxicity, and cost in Methods and Table 1. Life expectancy, QALYs, and costs all discounted at 3%/year. ART: antiretroviral
therapy; QALY: Quality-adjusted life year; Dominated: Less effective and more costly than the standard of care ART strategy.
doi:10.1371/journal.pone.0113031.t002
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below 40%. At cure efficacy of 40%, Chemotherapy would
achieve an ICER below $100,000/QALY gained with improve-
ment in QOL utility to 0.88. If we used ICER thresholds below
$150,000 or $200,000 per QALY gained to define cost-effective-
ness, there were no appreciable changes in results [15].
Discussion
With intense pre-clinical investigation underway towards
finding a cure for HIV, we sought to evaluate the cost-effectiveness
of three potential HIV cure approaches, each compared to
standard of care ART. We used a variety of assumptions,
anchored in published data on gene-targeted therapy, chemother-
apy, and stem cell transplant for diseases other than HIV. By
doing extensive sensitivity analyses on efficacy, toxicity, relapse
rates, and cost, we defined a range of benchmarks that might
justify the adoption of a cure strategy, and identified combinations
of parameters under which these could potentially be cost-effective
or cost-saving. For a Gene Therapy approach, modest increases in
efficacy (above 10%) or moderate decreases in cost (below
$100,000), led to this strategy being cost-saving compared to
ART. For Chemotherapy and SCT, the inventions became cost-
saving with very high efficacies and low relapse rates.
Table 3. Threshold which key parameters would need to reach for each type of HIV cure strategy to be cost-effective (ICER,
$100,000/QALY gained) or cost-saving.
Parameter Base case value ICER,$100,000/QALY gained Cost-saving
Gene Therapy (base case ICER: $330,600/QALY gained)
Efficacy (%) 10 22 34
Fatal Toxicity (%) 0.0 None None
Monthly relapse rate (%),
early (late)
0.5/0.25 None None
Intervention cost ($) 100,000, one-time 54,000, one-time 34,000, one-time
Chemotherapy (base case ICER: Dominated)
Efficacy (%) 20 88 None
Fatal Toxicity (%) 1.2 None None
Monthly relapse rate (%),
early (late)
0.5/0.25 None None
Intervention cost ($) 12,400/month,
for 24 months
**
Stem Cell Transplant (base case ICER: Dominated)
Efficacy (%) 70 79 80
Fatal Toxicity (%) 5.0 3.0 None
Monthly relapse rate (%),
early (late)
0.5/0.25 None 0.25/0.125
Intervention cost ($) 150,000, one-time * *
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; QOL: quality of life; Dominated: strategy was less effective and more expensive than
current ART.
*Cost reductions led to the strategy being less effective and less expensive than current ART. One could calculate an ICER for ART compared to Chemotherapy or Stem
Cell Transplant, but it is not clinically plausible that these strategies would be used if they resulted in worse outcomes than standard of care with ART, even if they saved
money by avoiding the costs of lifelong ART.
doi:10.1371/journal.pone.0113031.t003
Figure 1. Gene Therapy compared to standard of care ART. The figure depicts the cost-effectiveness of Gene Therapy compared to standard
of care ART as a function of the three influential parameters identified via the one-way sensitivity analysis in Table 3: cost, relapse rate, and efficacy. In
each panel, the horizontal axis denotes efficacy while the vertical axis denotes the relapse rate. Inside each panel, the shading denotes the resultant
cost-effectiveness finding, ranging from cost-saving (green), through cost-effective (with an ICER,$100,000/QALY, yellow), to not cost-effective ($
$100,000/QALY or more expensive and less effective than ART, red). ART: antiretroviral therapy; ICER: incremental cost-effectiveness ration; QALY:
quality-adjusted life year.
doi:10.1371/journal.pone.0113031.g001
HIV Cure Strategies Compared to ART
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e113031We found that changes in efficacy, relapse rates, and/or cost
rapidly moved the strategies from being worse than ART to being
cost-saving – that is, to being both equally or more effective and
less costly. The range in which any strategy would be cost-effective
but not cost-saving is narrow (Figures 1–3, yellow area). High
initial costs of cure strategies could be justified, and would save
money, if (and essentially only if) the strategy eliminates the
lifetime cost of ART. For example, with an initial cost of $100,000
and an efficacy of 34%, the Gene Therapy strategy is cost-saving
compared to ART, even if all other assumptions remain the same.
In such a scenario, identification of conditions that could
theoretically increase the likelihood of cure – such as ART started
during acute infection, or heterozygosity of the CCR5delta32 gene
– would make a cure strategy even more attractive [38].
Alternatively a substantial decrease in the cost of lifelong ART
would make these interventions less cost-effective.
It is possible that combination approaches to cure may be
needed to improve efficacy [39]. These would, nonetheless, each
have some combination of efficacy, toxicity, and cost. The value in
terms of cost-effectiveness, compared to ART, can be inferred
from those combinations as shown in Figures 1–3. Further, some
lower-risk interventions, such as zinc finger nucleases, could also
have higher efficacy than other interventions. If so, then they
would both be more effective and less costly, and thus ‘dominant’
from a cost-effectiveness perspective, compared to those other
interventions, such as HDAC inhibitors.
No published studies to date have examined the cost-effective-
ness of hypothetical HIV cure strategies in comparison to ART.
Similar model-based analyses have, however, been done for other
previously unproven strategies in HIV, including therapeutic and
preventive HIV vaccines and pre-exposure prophylaxis (PrEP)
[40–42]. These analyses have been used to design subsequent
vaccine and PrEP research. In the case of PrEP, modeled results
before proven efficacy closely matched the outcome of some later
trials [43].
At present, strategies to cure HIV have only progressed to the
proof of concept stage. Given this early stage, current complexity,
anticipated cost, and possible risks, a cure strategy will not be
ready for implementation anytime soon. However, this analysis
suggests that potential HIV cure strategies must be moderately
effective and have low toxicity and low relapse rates to compare
favorably to standard of care ART. The optimal cost threshold for
such strategies will depend on both the likelihood of durable cure
(initial efficacy and subsequent relapse rate) and the cost of ART.
As initial efforts at cure are developed, this work can help
investigators determine the efficacy and toxicity targets which
would make the strategies attractive. Further, if any cure strategies
are proven effective, the results of this analysis can help inform
policymakers as to their appropriate role. This issue has recently
been highlighted by the high efficacy and cost of new HCV cures
[44].
From a societal and quality-of-life perspective, with a base case
utility of 0.85 for patients doing well on ART, improvements in
Figure 2. Chemotherapy compared to standard of care ART. The figure depicts the cost-effectiveness of Chemotherapy compared to
standard of care ART as a function of the three influential parameters identified via the one-way sensitivity analysis in Table 3: cost, relapse rate, and
efficacy. In each panel, the horizontal axis denotes efficacy while the vertical axis denotes the relapse rate. Inside each panel, the shading denotes the
resultant cost-effectiveness finding, ranging from cost-saving (green), through cost-effective (with an ICER,$100,000/QALY, yellow), to not cost-
effective ($$100,000/QALY or more expensive and less effective than ART, red). ART: antiretroviral therapy; ICER: incremental cost-effectiveness
ration; QALY: quality-adjusted life year.
doi:10.1371/journal.pone.0113031.g002
Figure 3. Stem Cell Transplantation compared to standard of care ART. The figure depicts the cost-effectiveness of Stem Cell
Transplantation compared to standard of care ART as a function of the three influential parameters identified via the one-way sensitivity analysis in
Table 3: cost, relapse rate, and efficacy. In each panel, the horizontal axis denotes efficacy while the vertical axis denotes the relapse rate. Inside each
panel, the shading denotes the resultant cost-effectiveness finding, ranging from cost-saving (green), through cost-effective (with an ICER,$100,000/
QALY, yellow), to not cost-effective ($$100,000/QALY or more expensive and less effective than ART, red). Instances where the intervention is both
less expensive and less effective than ART are denoted in blue, but most were not cost-effective because the ICER of ART was ,$100,000/QALY
compared to SCT. The plus sign indicates a strategy that had an ICER for ART compared to SCT .$100,000/QALY gained. ART: antiretroviral therapy;
ICER: incremental cost-effectiveness ration; QALY: quality-adjusted life year.
doi:10.1371/journal.pone.0113031.g003
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effectiveness. However, many might argue that there is an
important psychological, social, and emotional distinction to be
drawn between curing HIV and controlling it via therapy.
Our study has several limitations. The most important is that
HIV cure interventions do not yet exist, so model parameters such
as efficacy, mortality, cost, and relapse rates were assumed using
specific data wherever possible and then varied widely. The effect
of cure strategies on the incidence and severity of ‘‘non-HIV’’
complications, such as malignancies, heart disease, and other
chronic non-communicable diseases was not included; one might
anticipate either an increase or decrease in these complications,
based on the strategy employed. If non-AIDS events are driven
primarily by HIV-mediated immune activation and inflammation,
then curing HIV would presumably ameliorate these processes. In
addition, adverse effects of antiretroviral drugs would also be
eliminated. By contrast, some of the treatments proposed for HIV
cure may themselves increase risks of non-AIDS events. For
example, some are analogous to cancer chemotherapy, and such
treatments may increase the risk of secondary malignancies;
radiation used for stem cell transplant could also raise cardiovas-
cular risk; and alteration in stem cells could also increase the long-
term risk of cancers. The demographics of the suppressed patients
eligible for cure interventions were based on the demographics of
the population presenting to care in the United States and may not
be completely representative of those who achieve suppression
after one year. Since we modeled only patients virologically
suppressed after a year, this represents the most adherent subset of
patients. If cure strategies were utilized in a broader group of
patients, such as those with early infection, the strategies might be
more or less effective and cost-effective compared to ART,
depending on the requirements of the particular cure strategy.
Gene therapy may require stem cell modification to achieve cure,
which could increase the risk of rare but substantial toxicity of
cancer induction; this risk was not included. Although we did
include relapse rates – indicating a later chance of HIV viral
rebound after initial cure – we did not include the possibility of re-
infection among cured patients, which has been documented after
successful HCV cure [45]. Adding this possibility would make any
cure strategy less attractive. Increased use of newer, more effective
branded therapies, however, may keep the costs of ART in their
current range [20].
In summary, the key determinants of the cost-effectiveness of
HIV cure strategies, compared to current antiretroviral therapy,
are initial efficacy, toxicity, relapse rate, and cost. Potential cure
strategies must have moderate efficacy, low toxicity, and relatively
low risk of relapse to be cost-effective and, in combination, would
likely be cost-saving.
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